Last reviewed · How we verify
Hydroxocobalamin Chloride Injection
Hydroxocobalamin chloride is a form of vitamin B12 that replaces deficient cobalamin and restores normal cellular metabolism and neurological function.
Hydroxocobalamin chloride is a form of vitamin B12 that replaces deficient cobalamin and restores normal cellular metabolism and neurological function. Used for Vitamin B12 deficiency, Pernicious anemia, B12 deficiency-related neurological complications.
At a glance
| Generic name | Hydroxocobalamin Chloride Injection |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Drug class | Vitamin B12 (cobalamin) supplement |
| Target | Cobalamin-dependent enzymes (methionine synthase, methylmalonyl-CoA mutase) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Nutritional deficiency |
| Phase | Phase 3 |
Mechanism of action
Hydroxocobalamin is a naturally occurring form of vitamin B12 (cobalamin) that serves as a cofactor for critical enzymatic reactions including methionine synthase and methylmalonyl-CoA mutase. It is used to treat vitamin B12 deficiency states, which can result from pernicious anemia, malabsorption, dietary insufficiency, or other causes. By replenishing intracellular cobalamin stores, it corrects metabolic dysfunction and prevents or reverses neurological complications associated with B12 deficiency.
Approved indications
- Vitamin B12 deficiency
- Pernicious anemia
- B12 deficiency-related neurological complications
Common side effects
- Injection site reactions (pain, erythema)
- Headache
- Dizziness
- Hypokalemia (rare, in severe deficiency)
Key clinical trials
- Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (PHASE2)
- Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma (PHASE2)
- A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type) (PHASE3)
- Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC (PHASE3)
- Study on the Improvement of Microcirculation in Patients With Sepsis by Vitamin B6, Vitamin B12 and Vitamin C (NA)
- Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) (PHASE3)
- Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study (PHASE3)
- Tolerability and Efficacy of RJX in Patients With COVID-19 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: